Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 4/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986518 | 0.88 | GRIK1 (0.33) | SLC1A3SLC1A2SLC1A1MMEGRIK1 | |
| SCHEMBL4986679 | 0.86 | GRIK1 (0.33) | SLC1A3SLC1A2SLC1A1MMEGRIK1 | |
| SCHEMBL4981583 | 0.84 | SLC1A3 (0.33) | SLC1A3SLC1A2SLC1A1MMEGRIK1 | |
| SCHEMBL27644730 | 0.83 | SLC1A3 (0.41) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL4989038 | 0.83 | SLC1A3 (0.34) | SLC1A3SLC1A2SLC1A1MMEGRIK1 | |
| SCHEMBL4987733 | 0.83 | KDM4E (0.31) | SLC1A3SLC1A2MMEGRIK1GRIK2 | |
| SCHEMBL4994948 | 0.81 | KDM4E (0.30) | MME | |
| SCHEMBL4990909 | 0.81 | MME (0.38) | MMEGRIK1GRIK2LMNACYP1A2 | |
| SCHEMBL4992273 | 0.80 | LMNA (0.41) | LMNA | |
| SCHEMBL4987148 | 0.80 | MEN1 (0.43) | GRIK1GRIK2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | SLC1A3 118/4885SLC1A2 57/4885SLC1A1 106/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | SLC1A3 128/4885SLC1A2 42/4885SLC1A1 111/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | SLC1A3 104/4885SLC1A2 29/4885SLC1A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.